Humacyte, Inc. Terminates Material Definitive Agreement
Ticker: HUMAW · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1818382
| Field | Detail |
|---|---|
| Company | Humacyte, Inc. (HUMAW) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50, $80,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
Related Tickers: HUMA
TL;DR
Humacyte terminated a big deal, could be bad.
AI Summary
Humacyte, Inc. announced on November 21, 2025, the termination of a material definitive agreement. The company, previously known as Alpha Healthcare Acquisition Corp., is incorporated in Delaware and headquartered in Durham, NC.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals significant business challenges or a change in strategic direction, which carries inherent risk.
Key Players & Entities
- Humacyte, Inc. (company) — Registrant
- Alpha Healthcare Acquisition Corp. (company) — Former company name
- November 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Durham, NC (location) — Business address city and state
FAQ
What was the specific material definitive agreement that Humacyte, Inc. terminated?
The filing states the termination of a material definitive agreement but does not specify which agreement was terminated.
When did the termination of the material definitive agreement become effective?
The report indicates November 21, 2025, as the date of the earliest event reported, which is the termination.
What is Humacyte, Inc.'s primary business?
Humacyte, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
What was Humacyte, Inc.'s former name?
Humacyte, Inc.'s former name was Alpha Healthcare Acquisition Corp.
Where is Humacyte, Inc. headquartered?
Humacyte, Inc. is headquartered at 2525 East North Carolina Highway 54, Durham, NC 27713.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-11-26 17:01:04
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share HUMA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 HUMAW The Nasdaq Stock Market LLC
- $80,000,000 — ng an aggregate offering price of up to $80,000,000 during the term of the Agreement throug
Filing Documents
- tm2532300d1_8k.htm (8-K) — 28KB
- 0001104659-25-116476.txt ( ) — 238KB
- huma-20251121.xsd (EX-101.SCH) — 4KB
- huma-20251121_def.xml (EX-101.DEF) — 26KB
- huma-20251121_lab.xml (EX-101.LAB) — 37KB
- huma-20251121_pre.xml (EX-101.PRE) — 25KB
- tm2532300d1_8k_htm.xml (XML) — 6KB
02. Termination of a Material Definitive Agreement
Item 1.02. Termination of a Material Definitive Agreement As previously disclosed, on September 1, 2022, Humacyte, Inc. (the "Company") entered into an Open Market Sale Agreement (the "Agreement") with Jefferies LLC ("Jefferies"), under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $80,000,000 during the term of the Agreement through Jefferies, acting as agent. On November 21, 2025, the Company delivered a notice to Jefferies terminating the Agreement, which termination will become effective under the Agreement 10 days thereafter. The Company is not subject to any termination penalties related to the termination of the Agreement. A copy of the Agreement was filed as Exhibit 1.2 to the Company's Registration SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HUMACYTE, INC. Date: November 26, 2025 By: /s/ Dale A. Sander Name: Dale A. Sander Title: Chief Financial Officer, Chief Corporate Development Officer and Treasurer